- Home
- FDMT vs ACIU Comparison
FDMT vs ACIU Comparison
Compare FDMT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- ACIU
- Stock Information
- Founded
- FDMT 2013
- ACIU 2003
- Country
- FDMT United States
- ACIU Switzerland
- Employees
- FDMT N/A
- ACIU N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- ACIU Health Care
- Exchange
- FDMT Nasdaq
- ACIU Nasdaq
- Market Cap
- FDMT 207.1M
- ACIU 168.7M
- IPO Year
- FDMT 2020
- ACIU 2016
- Fundamental
- Price
- FDMT $4.13
- ACIU $1.88
- Analyst Decision
- FDMT Buy
- ACIU Strong Buy
- Analyst Count
- FDMT 10
- ACIU 1
- Target Price
- FDMT $32.33
- ACIU $12.00
- AVG Volume (30 Days)
- FDMT 449.2K
- ACIU 116.1K
- Earning Date
- FDMT 08-07-2025
- ACIU 08-05-2025
- Dividend Yield
- FDMT N/A
- ACIU N/A
- EPS Growth
- FDMT N/A
- ACIU N/A
- EPS
- FDMT N/A
- ACIU N/A
- Revenue
- FDMT $23,000.00
- ACIU $32,014,254.00
- Revenue This Year
- FDMT $13,048.65
- ACIU N/A
- Revenue Next Year
- FDMT N/A
- ACIU $533.21
- P/E Ratio
- FDMT N/A
- ACIU N/A
- Revenue Growth
- FDMT N/A
- ACIU 91.20
- 52 Week Low
- FDMT $2.24
- ACIU $1.43
- 52 Week High
- FDMT $28.93
- ACIU $4.41
- Technical
- Relative Strength Index (RSI)
- FDMT 54.45
- ACIU 51.75
- Support Level
- FDMT $4.21
- ACIU $1.83
- Resistance Level
- FDMT $4.62
- ACIU $2.10
- Average True Range (ATR)
- FDMT 0.30
- ACIU 0.15
- MACD
- FDMT -0.02
- ACIU -0.00
- Stochastic Oscillator
- FDMT 37.42
- ACIU 44.44
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.